EPIX

ESSA Pharma Inc. (EPIX) | Rumor.io

ESSA Pharma

EPIX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EPIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Oct 9

ESSA Pharma Inc. ($EPIX) has completed its arrangement with XenoTherapeutics, with shareholders receiving $0.1242 per share and potential additional payments up to $0.14 per share through a contingent value right (CVR).
The acquisition has resulted in the delisting of EPIX, with the company's value decreasing by nearly 99% over the past five years.
Shareholders who held EPIX during this time are being advised to be cautious of potential risks and consequences, as demonstrated by a tragic case where an individual's losses in EPIX led to financial ruin.

Generated by AI

Sentiment

Of the messages about EPIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% new	73.86% +6.57
Bearish	0%	0%	0% -100	26.14% -6.57

Bullish· Aug 27

$EPIX has strong potential for a thousand-bagger due to its market cap of $11 million and the scale of its $10 billion play.
With $32 million in cash on hand, the company has a solid financial foundation to support its growth and development.
As a biotech company with a promising pipeline and positive clinical updates, $EPIX is poised for near-term momentum and long-term success.

Bearish· Aug 26

$EPIX tanked -70% and millions of traders were trapped, indicating a significant decline in value.
The company's payout value came off the stock after ex-dividend trading resumed, leading to a ~60% price drop due to low float and thin liquidity.
$EPIX's decline was magnified by the company winding down, with major resistance at $0.279 and the likelihood of it recovering being uncertain.

Generated by AI

Topics

Of the messages about EPIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	17.1%
Announcements	—	—	—	69.34%
Controversies	—	—	—	7.08%
Earnings	—	—	—	0.24%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.25%

Announcements· Aug 26

ESSA Pharma Inc. clarified the Nasdaq due-bill trading period for its previously announced $80 million cash distribution.
The company's shares are trading lower after announcing the $80 million capital distribution, which was paid ex-dividend as of August 25.
ESSA Pharma's shares are down today, but the company has $120.6 million in cash reserves, and its merger with XenoTherapeutics is advancing.

Technical Analysis· Nov 1

$EPIX is in a downtrend, with lower highs and rejections, and may drop further after breaking its higher Bollinger Band on October 26, 2022.
The stock has shown a bull flag formation and is awaiting a buy signal based on 18 signals on the 15-min chart, with a possible multi-day trend breakout on volume.
$EPIX is oversold according to the RSI indicator, indicating a possible move higher, and has a 15/30/45/FIB indicating an uptrend, with some traders expecting a bounce from the pre-market sell off.

Generated by AI

Community

Of the messages about EPIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	13.65%
Newcomers	100%	100%	100%	86.35%

Regulars· Aug 26

ESSA Pharma Inc.'s stock price dropped by 64.47% to $0.28 on August 26, 2025.
The company clarified the due bill trading period for its previously announced cash distribution of $80 million.
The cash distribution is a key event in the company's XenoTherapeutics deal, which may impact its stock price.

Newcomers· Aug 27

$EPIX stock is experiencing a 60% drop, according to Quiver Quantitative, which is analyzing the data behind the decline.
Newcomers are confused about the company's dividend policy, with one person asking why the dividend amount was dropped after the ex-dividend date and another questioning the timing of the disbursement date.
The stock is seeing a surge in pre-market trading due to positive clinical developments and strategic biotech partnerships, with one user describing it as a "breakout" and encouraging traders to act on the momentum.

Generated by AI

Also Discussed

Investors talking about EPIX also mention

#	Name	Attention
1	HeartCore Enterprises, Inc.HTCR	0%0
2	PMV Pharmaceuticals, Inc.PMVP	0%0
3	JNCE - Jounce Therapeutics, Inc.	——
4	Chunghwa Telecom Co., Ltd. ADRCHT	0%0
5	Keros Therapeutics, Inc.KROS	0%new
6	JBT - JBT Marel Corporation	——
7	ALPS Medical Breakthroughs ETFSBIO	0%new
8	RPHM - Reneo Pharmaceuticals, Inc.	——
9	CompX International Inc.CIX	0%0
10	KNTE - Kinnate Biopharma Inc.	——

ESSA Pharma Inc.

Location

Social

What share of all stock conversation is about EPIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Oct 9

ESSA Pharma Inc. ($EPIX) has completed its arrangement with XenoTherapeutics, with shareholders receiving $0.1242 per share and potential additional payments up to $0.14 per share through a contingent value right (CVR).
The acquisition has resulted in the delisting of EPIX, with the company's value decreasing by nearly 99% over the past five years.
Shareholders who held EPIX during this time are being advised to be cautious of potential risks and consequences, as demonstrated by a tragic case where an individual's losses in EPIX led to financial ruin.

Generated by AI

Sentiment

Of the messages about EPIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% new	73.86% +6.57
Bearish	0%	0%	0% -100	26.14% -6.57

Bullish· Aug 27

$EPIX has strong potential for a thousand-bagger due to its market cap of $11 million and the scale of its $10 billion play.
With $32 million in cash on hand, the company has a solid financial foundation to support its growth and development.
As a biotech company with a promising pipeline and positive clinical updates, $EPIX is poised for near-term momentum and long-term success.

Bearish· Aug 26

$EPIX tanked -70% and millions of traders were trapped, indicating a significant decline in value.
The company's payout value came off the stock after ex-dividend trading resumed, leading to a ~60% price drop due to low float and thin liquidity.
$EPIX's decline was magnified by the company winding down, with major resistance at $0.279 and the likelihood of it recovering being uncertain.

Generated by AI

Topics

Of the messages about EPIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	17.1%
Announcements	—	—	—	69.34%
Controversies	—	—	—	7.08%
Earnings	—	—	—	0.24%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.25%

Announcements· Aug 26

ESSA Pharma Inc. clarified the Nasdaq due-bill trading period for its previously announced $80 million cash distribution.
The company's shares are trading lower after announcing the $80 million capital distribution, which was paid ex-dividend as of August 25.
ESSA Pharma's shares are down today, but the company has $120.6 million in cash reserves, and its merger with XenoTherapeutics is advancing.

Technical Analysis· Nov 1

$EPIX is in a downtrend, with lower highs and rejections, and may drop further after breaking its higher Bollinger Band on October 26, 2022.
The stock has shown a bull flag formation and is awaiting a buy signal based on 18 signals on the 15-min chart, with a possible multi-day trend breakout on volume.
$EPIX is oversold according to the RSI indicator, indicating a possible move higher, and has a 15/30/45/FIB indicating an uptrend, with some traders expecting a bounce from the pre-market sell off.

Generated by AI

Community

Of the messages about EPIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	13.65%
Newcomers	100%	100%	100%	86.35%

Regulars· Aug 26

ESSA Pharma Inc.'s stock price dropped by 64.47% to $0.28 on August 26, 2025.
The company clarified the due bill trading period for its previously announced cash distribution of $80 million.
The cash distribution is a key event in the company's XenoTherapeutics deal, which may impact its stock price.

Newcomers· Aug 27

$EPIX stock is experiencing a 60% drop, according to Quiver Quantitative, which is analyzing the data behind the decline.
Newcomers are confused about the company's dividend policy, with one person asking why the dividend amount was dropped after the ex-dividend date and another questioning the timing of the disbursement date.
The stock is seeing a surge in pre-market trading due to positive clinical developments and strategic biotech partnerships, with one user describing it as a "breakout" and encouraging traders to act on the momentum.

Generated by AI

ESSA Pharma

Social

Oct 9

Sentiment

Bullish· Aug 27

Bearish· Aug 26

Topics

Announcements· Aug 26

Technical Analysis· Nov 1

Community

Regulars· Aug 26

Newcomers· Aug 27

Also Discussed

ESSA Pharma Inc.

Company Information

Location

Also Discussed

Social

Oct 9

Sentiment

Bullish· Aug 27

Bearish· Aug 26

Topics

Announcements· Aug 26

Technical Analysis· Nov 1

Community

Regulars· Aug 26

Newcomers· Aug 27